IDH1 and cancer: For example, AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme, has an acceptable safety profile and clinical activity, according to preliminary data from a Phase I clinical trial recruiting cancer patients with the IDH1 mutation (Popovici-Muller et al., 2018).